

COURSE DIRECTOR

Walter J. Scott, MD, FACS

Gloria and Edmund M. Dunn Chair
Chief, Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

COURSE CO-DIRECTORS

Hossein Borghaei, DO, MS

Director, Thoracic, Medical Oncology
Co-Leader, Thoracic Cancer Service Line
Fox Chase Cancer Center
Philadelphia, PA

Prashant C. Shah, MD

Attending Surgeon
Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

FACULTY

Matthew P. Bars, MS, CTTS

Director, Tobacco Treatment Program
New York City Fire Department
Director of IQuit Smoking Center of
Excellence
Brooklyn, NY

Alan D. Haber, MD, FCCP

Director, Pulmonary Service
Medical Director, Intensive Care Unit
Department of Medicine
Fox Chase Cancer Center
Philadelphia, PA

Shelly B. Hayes, MD

Director, Fox Chase Cancer Center
Buckingham
Department of Radiation Oncology
Fox Chase Cancer Center
Philadelphia, PA

Paul A. Kvale, MD

Senior Staff Physician
Henry Ford Hospital
Principal Investigator, National Lung
Screening Trial
Detroit, MI

Corey J. Langer, MD, FACP

Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Hematology Oncology Division
University of Pennsylvania
Philadelphia, PA

Ranee Mehra, MD

Attending Physician
Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Gaëtane Celine Michaud, MD, FRCP

Assistant Professor, Medicine,
Harvard Medical School
Harvard Medical Faculty Physicians at
Beth Israel Deaconess Medical Center
Boston, MA

Barton N. Milestone, MD

Vice Chairman, Department of Radiology
Director of MRI
Fox Chase Cancer Center
Philadelphia, PA

Aruna Turaka, MD

Attending Physician
Radiation Oncology
Fox Chase Cancer Center
Philadelphia, PA

Michael Unger, MD, FACP, FCCP

Director, Pulmonary Cancer Detection
and Prevention Program
Director, Pulmonary Endoscopy and
High-Risk Lung Cancer Program
Department of Medicine
Fox Chase Cancer Center
Philadelphia, PA

THIRD ANNUAL FOX CHASE CANCER CENTER

ADVANCES IN THORACIC ONCOLOGY CONFERENCE

CONTROVERSIES AND CHALLENGES IN THE MANAGEMENT OF THORACIC DISEASE

FRIDAY, APRIL 29, 2011



LOCATION

Pennsylvania Convention Center
1101 Arch Street | Philadelphia, PA 19107

Sponsored by

FOX CHASE
CANCER CENTER

Philadelphia, PA

*At the time of publication, the following companies have
provided educational grants to support this activity:*
Genentech

STATEMENT OF NEED

Evolving medical, surgical, radiation and screening advances continue to expand our ability to diagnose, evaluate, stage and treat thoracic cancers and improve patient outcomes. Having more options can lead to controversies about the benefits and risks of individual techniques and challenges in determining the appropriate strategies for managing these patients.

- The National Lung Screening Trial (NLST) demonstrated benefits to overall survival for some patients. However, there are controversies about who should be screened, the appropriate methods of evaluation and concerns about how to counsel patients about the effects of screening.
- There are a variety of methods to evaluate a solitary pulmonary nodule, and each option has benefits and risks. It can be challenging to determine which patients are candidates for specific tests.
- There are challenges to implementing a smoking cessation program in professional practice. Counseling should be coordinated with stages of readiness for change to ensure success. There are coding, billing and reimbursement issues that are difficult to navigate.
- Although options for evaluating and managing stage III non-small cell lung cancer (NSCLC) have increased, clinicians are faced with challenges in identifying the most appropriate methods for individual patients.
- New chemotherapeutic options continue to emerge for lung disease. New tests for identifying patients who will respond to specific therapies continue to show promise. New personalized therapies are evolving and expand the available treatment options. Recent clinical trials suggest that maintenance chemotherapy prolongs survival in patients with advanced NSCLC. Clinicians are challenged to evaluate the appropriate course of treatment for stage IV NSCLC patients.
- There are controversies about the best way to manage high-risk early stage NSCLC. Is stereotactic body radiation therapy versus surgery the better way to manage these patients or is a combined modality approach more beneficial?

We have designed this conference to examine some of the dilemmas in thoracic oncology; to assist clinicians to diagnose, evaluate, stage and manage patients with lung cancer, mesothelioma and asbestos exposure; and to enhance physicians' ability to counsel their patients about available treatments. We will incorporate case presentations using audience response technology to enhance the discussion. There will be ample time for participants to ask questions and interact with the speakers. Participants are encouraged to submit interesting cases for discussion.

ACCREDITATION STATEMENT

The Fox Chase Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. i

OBJECTIVES

After completing this activity, participants should be able to:

1. Review current controversies pertaining to lung cancer screening and the benefits to overall survival based on the results of the National Lung Screening Trial (NLST) to determine when lung screening is appropriate and to discuss the effects of screening with patients, in particular those with asbestos exposure.
2. Determine the appropriate strategies to screen for a solitary pulmonary nodule (SPN) to differentiate between benign and malignant characteristics of suspicious lung nodules.
3. Assess patients using the stages of readiness for change when conducting smoking cessation counseling.
4. Integrate appropriate coding, billing and reimbursement procedures when developing a smoking cessation program.
5. Compare endobronchial and surgical options to evaluate mediastinal involvement in patients with Stage III NSCLC to improve patient outcomes.
6. Determine whether induction therapy should be given before or after mediastinoscopy.
7. When preparing treatment plans, compare available chemotherapy options for minimizing toxicity and maximizing treatment effect for patients receiving concurrent chemoradiation.
8. Integrate the use of toxicity profiles to address mediastinoscopy in radiation treatment planning.
9. Compare the benefits and risks of new therapeutic options and maintenance therapy for the management of stage IV lung cancer and, when clinically relevant, include these in treatment plans to maximize treatment effect and improve patient outcomes.
10. Compare the benefits and risks of stereotactic body radiation, minimally invasive surgery and combined modality treatment to determine the appropriate management plans for patients with high-risk, early stage NSCLC.

TARGET AUDIENCE

This program is designed for medical and radiation oncologists, general and thoracic surgeons, pulmonologists, and other physicians involved in the management of patients with lung cancer, mesothelioma and other lung disorders, including solitary pulmonary nodules and asbestos exposure. Fellows, residents, students, physician assistants, nurse practitioners, nurses and other health professionals involved in the management of these patients may find the program beneficial.

DESIGNATION STATEMENT

The Fox Chase Cancer Center designates this educational activity for a maximum of **8.00 AMA PRA Category 1 Credit(s)**[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FOX CHASE
CANCER CENTER

Philadelphia, PA • www.fccc.edu

Telephone: 215-728-5358 • Fax: 215-214-8908

REGISTRATION AND PAYMENT

Please send Registration Form with check payable to **Fox Chase Cancer Center**, Attn: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. **(Credit cards not accepted.)**

Registration Fees:

Includes program materials, continental breakfast, breaks and lunch.

	Physicians PA's/Nurses	Fellows Residents/Students
Registration Fee, Payment received by 4/28/2011	\$125	\$60
Onsite Fee, Payment received 4/29/2011	\$150	\$75
FCCC PARTNER (FCCC Partner affiliation required)	\$100	

Registration Deadline: April 21, 2011

Cancellations received prior to April 21 will be refunded in full.

INQUIRIES

Office of Continuing Medical Education, Fox Chase Cancer Center
Telephone: 215-728-5358; Fax: 215-214-8908;
E-mail: CME@fcc.edu

INTERESTING CASES

If you have an interesting case that you would like us to consider for discussion, please send a description of the case by **April 1, 2011** to the Office of CME, Email: CME@fcc.edu; Fax: 215-214-8908.

DIRECTIONS/PARKING

Directions/Parking are available at www.paconvention.com (Click **Attendees**).

FOX CHASE CANCER CENTER DISCLOSURE POLICY

It is the policy of Fox Chase Cancer Center to ensure that all sponsored continuing medical education activities are independently designed and produced and include valid content that is objective, balanced, free of commercial bias and in the best interest of the public. Fox Chase Cancer Center policy requires everyone in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest pertaining to the content of the activity. Individuals who refuse to disclose cannot have control of or responsibility for activity content. Conflicts of interest will be resolved prior to the activity. Fox Chase Cancer Center requires disclosure to the activity audience of relevant financial relationships of those with control over CME content and support from commercial interests.

PROGRAM

7:30 am	Registration and Continental Breakfast
8:00 am	Introduction & Welcome Walter J. Scott, MD, FACS

8:15-9:40am SESSION 1 SCREENING FOR LUNG CANCER & MESOTHELIOMA: WHAT DO I SAY WHEN PATIENTS ASK?

Moderator: Hossein Borghaei, DO

8:15-8:20 am	Case Scenarios
8:20 am	Background and Results of the National Lung Screening Trial Paul A. Kvale, MD
8:40 am	Mesothelioma: Screening Patients with a History of Asbestos Exposure Michael Unger, MD, FACP, FCCP
9:00 am	How to Counsel Patients About Lung Cancer Screening and Effects of Screening on Behavior Paul A. Kvale, MD
9:20 am	Case Scenarios & Panel Discussion
9:40-9:55 am	BREAK

9:55-11:40am SESSION 2 EVALUATION OF THE PATIENT WITH A SOLITARY PULMONARY NODULE (SPN)

Moderator: Walter J. Scott, MD, FACS

9:55-10:00 am	Case Scenarios
10:00 am	The Pulmonologist's Point of View Alan D. Haber, MD, FCCP
10:20 am	The Radiologist's Point of View Barton N. Milestone, MD
10:40 am	The Interventional Pulmonologist's Point of View Gaëtane C. Michaud, MD, FRCP
11:00 am	The Surgeon's Point of View Prashant C. Shah, MD
11:20 am	Case Scenarios & Panel Discussion
11:40-12:55 pm	LUNCH and SPECIAL LECTURE: SMOKING CESSATION AND YOUR PRACTICE Matthew P. Bars, MS, CTTS Introduction: <i>Walter J. Scott, MD, FACS</i>

12:55-3:00 pm SESSION 3 EVALUATION & MANAGEMENT OF THE PATIENT WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)

Moderator: Prashant C. Shah, MD

12:55-1:00 pm	Case Scenarios
1:00 pm	EBUS, EUS and ENB for Staging the Mediastinum Michael Unger MD, FACP, FCCP
1:20 pm	Why We Still Need to Do Mediastinoscopy Prashant C. Shah, MD
1:40 pm	Strategies for Giving Radiation Therapy Concurrently with Chemotherapy for Stage III NSCLC Aruna Turaka, MD
2:00 pm	Chemotherapy Regimens for Use with Concurrent Radiation Therapy Ranee Mehra, MD
2:20 pm	Surgical Resection after Induction Therapy Walter J. Scott, MD, FACS
2:40 pm	Case Scenarios & Panel Discussion
3:00-3:15 pm	BREAK

3:15-4:00 pm SESSION 4 ADVANCES IN THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER

Moderator: Hossein Borghaei, DO

3:15-3:20 pm	Case Scenarios
3:20 pm	State-of-the-Art in the Treatment of Advanced Non-Small Cell Lung Cancer: 2011 Corey J. Langer, MD, FACP
3:40 pm	Novel Agents in Advanced NSCLC Hossein Borghaei, DO
4:00 pm	Case Scenarios & Panel Discussion

4:20-5:45 pm SESSION 5 MANAGEMENT OF THE HIGH-RISK EARLY STAGE NON-SMALL CELL LUNG CANCER PATIENT

Moderator: Hossein Borghaei, DO

4:20-4:25 pm	Case Scenarios
4:25 pm	DEBATE: Stereotactic Body Radiation Therapy (SBRT) is Better Shelly B. Hayes, MD
4:45 pm	DEBATE: Surgery is Better Walter J. Scott, MD, FACS
5:05 pm	Surgery and Stereotactic Body Radiation Therapy Aruna Turaka, MD
5:25 pm	Case Scenarios & Panel Discussion
5:45 pm	ADJOURN – COMPLETE EVALUATIONS

REGISTRATION FORM

Third Annual Fox Chase Cancer Center
ADVANCES IN THORACIC ONCOLOGY CONFERENCE

Name _____
Degree _____
Medical Specialty _____
(Please print/type name and degree as you would like them to appear on your nametag/certificate.)
Institution/Affiliation _____
Preferred Mailing Address _____
City _____
State _____ Zip _____
Daytime Phone _____
Fax _____
E-mail _____

Specify questions/issues you would like speakers to address.

REGISTRATION AND PAYMENT

Please send Registration Form with check payable to **Fox Chase Cancer Center**, Attn: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. **(Credit cards not accepted.)**

Registration Fees:

Includes program materials, continental breakfast, breaks and lunch.

	Physicians/PA's/Nurses	Fellows/Residents/Students
Registration Fee, Payment received by 4/28/2011	<input type="checkbox"/> \$125	<input type="checkbox"/> \$60
Onsite Fee, Payment received 4/29/2011	<input type="checkbox"/> \$150	<input type="checkbox"/> \$75
FCCC PARTNER (FCCC Partner affiliation required)	<input type="checkbox"/> \$100	

Indicate FCCC Partner affiliation

Registration Deadline: April 21, 2011.

Cancellations received prior to **April 21** will be refunded in full.

INQUIRIES: Office of CME, Fox Chase Cancer Center.
Phone: 215-728-5358; Fax: 215-214-8908, E-mail: CME@fcc.edu

SPECIAL NEEDS: Indicate auxiliary aids or services you require as identified in the Americans with Disabilities Act.

ADA Requirements:
(Specify) _____

Dietary: Kosher Vegetarian Other (Specify) _____